Savara Overview
- Founded
-
2007

- Status
-
Public
- Employees
-
35

- Stock Symbol
-
SVRA

- Investments
-
3
- Share Price
-
$2.64
- (As of Monday Closing)
Savara General Information
Description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Contact Information
- 6836 Bee Cave Road, Building 3
- Suite 201
- Austin, TX 78746
- United States
Savara Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.64 | $2.75 | $1.02 - $2.82 | $304M | 114M | 175K | -$0.25 |
Savara Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 60,369 | (3,926) | (6,883) | 146,739 |
Revenue | 0 | 0 | 257 | 0 |
EBITDA | (37,631) | (40,365) | (47,440) | (77,093) |
Net Income | (39,160) | (43,014) | (49,615) | (78,173) |
Total Assets | 147,758 | 176,598 | 97,745 | 136,203 |
Total Debt | 26,092 | 25,791 | 25,283 | 25,552 |
Savara Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Savara Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Savara Comparisons
Industry
Financing
Details
Savara Competitors (22)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
MannKind | Formerly VC-backed | Westlake Village, CA | 000 | 00000 | 000000 - 000 | 00000 |
0000 000000000000 | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 0000000000 0 | 000.00 |
0000000 | Formerly VC-backed | Stevenage, United Kingdom | 00 | 00000 | 000000&0 | 00000 |
0000000000 0000000 | Venture Capital-Backed | Brighton, United Kingdom | 00 | 0000 | 000000 - 000 | 0000 |
000000 000000 | Formerly VC-backed | Morristown, NJ | 0 | 00.000 | 000000 - 000 | 00.000 |
Savara Patents
Savara Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20200115412-A1 | Separation of vancomycin and its degradation products | Inactive | 15-Oct-2018 | 0000000000 | |
EP-3866829-A1 | Separation of vancomycin and its degradation products | Inactive | 15-Oct-2018 | 00000000 | |
US-20140014107-A1 | Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Active | 12-Jul-2011 | 00000000000 | |
US-8820323-B2 | Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Inactive | 12-Jul-2011 | 00000000000 | 00 |
US-8826904-B2 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Inactive | 12-Jul-2011 | A61K31/7036 | 00 |
Savara Executive Team (14)
Savara Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
An van Es-Johansson MD | Self | Board Member | 000 0000 |
David Ramsay | Savara | Board Member | 000 0000 |
Joseph McCracken | Self | Board Member | 000 0000 |
Matthew Pauls JD | Self | Chairman & Chief Executive Officer | 000 0000 |
Nevan Elam JD | Self | Board Member | 000 0000 |
Savara Signals
Savara Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Savara Investments & Acquisitions (3)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 25-Jul-2018 | 000000000 | Buildings and Property | 000000 00 | |
0000 00000000 | 27-Apr-2017 | 0000000000 | 00000 | Pharmaceuticals | 000000 00 |
Serendex Pharmaceuticals | 15-Jul-2016 | Merger/Acquisition | 000.00 | Buildings and Property | 000000 00 |
Savara Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
000000 | Pharmaceuticals | Austin, TX | 0000 |
Savara ESG
Risk Overview
Risk Rating
Updated May, 27, 2021
33.36 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile

Pharmaceuticals
Industry
00 of 947
Rank
Percentile

Biotechnology
Subindustry
00 of 427
Rank
Percentile
